Skip to main content
Equibles

MEDICAMEQ · Medicamen Biotech Limited · Financials

Use MEDICAMEQ with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MEDICAMEQ.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
281.65 INR +9.85 (+3.62%) At close · Nov 13
Rebalance outlook locked
Market Cap
3.82B INR
Shares
13.56M
Volume · Nov 13 11.51K Avg daily vol (3M) 47.73K

Income-statement, balance-sheet and cash-flow figures read from the company's own published financial reports.

Pull these statements through the financial statements API or MCP →
Revenue
1.98B +21.7%
FY2026 Revenue FY2022–FY2026
Net Income
96.41M +35.6%
FY2026 Net Income FY2022–FY2026
Operating Cash Flow
-331.72M -361.1%
FY2026 Operating Cash Flow FY2022–FY2026

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics
Annual Quarterly
Line Item TTM FY2026 FY2025 FY2024 FY2023 FY2022
INR 2.03B 1.98B 1.63B 1.79B 1.41B 1.15B
INR 72.04M 72.19M 70.66M 70.93M 63.67M 57.71M
INR 31.73M 34.97M 31.56M 43.97M 29.23M 14.01M
INR 124.25M 119.85M 98.8M 130.76M 170.45M 180.94M
INR 23.83M 21.88M 33.24M 35.82M 23.17M 31.97M
INR 108.3M 96.41M 71.08M 109.31M 148.44M 0
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2026: 63.8M in dividends.

Debt Profile

No verified debt profile is available yet. This does not establish that the company has no debt or covenants.